PURPOSE: In 2002, at the McGill University Health Centre, we began a program of hypofractionated radiotherapy for @entity1 with @entity263 as an alternative to conventionally fractionated radiotherapy. MATERIAL AND METHODS: Our initial hypofractionation regimen was 66 Gy given in 22 fractions, prescribed to the isocenter, delivered with 3D-conformal radiotherapy plan. The clinical target volume was the prostate gland and the planning target volume consisted of the clinical target volume plus a 7-mm margin in all directions. Hormonal therapy was not given to any @entity1 . RESULTS: The long-term results for this group of @entity1 confirmed the feasibility, good tolerance and excellent disease control of the regimen with the extra-benefit of being convenient to both @entity1 and the health system by shortening treatment duration. The outcomes of this approach stimulated us to use hypofractionation in @entity1 with intermediate-risk. Analysis of 100 intermediate-risk @entity1 receiving our hypofractionated radiotherapy regimen (no hormones) shows, at median follow-up of 75 months, 8-year biochemical recurrence free and @entity5 specific survival rates of 90% and 95%, respectively, with acceptable @entity137 . DISCUSSION: Our technique changed from 3D to intensity modulated radiotherapy with the dose adjusted to 60 Gy in 20 fractions. Lastly, we have expanded the program to high-risk @entity1 where IMRT treatments are given to the pelvic nodes (44 Gy in 20 fractions) with a simultaneous integrated boost delivery to the prostate (60 Gy in the same 20 fractions). Our long-term results have shown that moderate hypofractionated radiotherapy for @entity263 is safe and provides @entity5 control comparable to high-dose conventionally fractionated radiotherapy. This hypofractionated regimen has been routinely used in our institution.

Hypofractionated radiation therapy for XXXX : The McGill University Health Center experience.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer', 'low risk prostate cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'good tumor']
@entity263 :: (MESH:D011471,Disease) :: ['prostate cancer']
